How a personalized mRNA vaccine trains immunity against melanoma
Merck and Moderna announced on August 19 that their personalized melanoma therapy had met the primary goal of a phase 3 trial.
The experimental regimen combines intismeran autogene, an individualized mRNA neoantigen therapy, with the immunotherapy pembrolizumab for patients whose stage IIB–IV melanoma has been completely removed [3]. The phase 3 trial enrolled more than 1,000 patients at risk of recurrence and compared the…
The experimental regimen combines intismeran autogene, an individualized mRNA neoantigen therapy, with the immunotherapy pembrolizumab for patients whose stage IIB–IV melanoma has been completely removed [3]. The phase 3 trial enrolled more than 1,000 patients at risk of recurrence and compared the combination with pembrolizumab alone, but detailed phase 3 data had not yet been released at the time of reporting [4].
Why it matters: This is the first mRNA cancer vaccine reported to have reached this stage of development, potentially extending mRNA technology from infectious-disease prevention to individualized cancer treatment [4]. Because surgery may leave patients at risk of recurrence, the approach is designed to help the immune system recognize tumor-specific targets after removal [3][4].
Key insights: Researchers sequence tumor and healthy tissue to identify cancer-driving mutations, then use algorithms to select neoantigens associated with the individual tumor [4]. | An mRNA molecule encodes instructions for those targets, is packaged in a lipid nanoparticle and is injected to train the immune system to attack matching cancer cells [4]. | The phase 3 comparison tested the personalized vaccine plus pembrolizumab against pembrolizumab alone in more than 1,000 patients [4]. | The reported 49% reduction in recurrence or death should not be treated as a fully disclosed phase 3 estimate: one account associated it with five-year follow-up [3], while another said phase 3 details remained unreleased and linked 49% to the earlier phase 2 trial [4].
Cheatsheet facts: What changed: The personalized mRNA regimen met the primary goal of a phase 3 melanoma trial, according to the companies, although detailed data were still pending [4]. | Why now: More than 1,000 post-surgery patients were studied, moving individualized neoantigen therapy to the final clinical-testing stage before a potential FDA request [4]. | Watch next: Watch for presentation of the complete phase 3 efficacy and safety data, followed by any FDA submission and evaluation [4].
The experimental regimen combines intismeran autogene, an individualized mRNA neoantigen therapy, with the immunotherapy pembrolizumab for patients whose stage IIB–IV melanoma has been completely removed [3]. The phase 3 trial enrolled more than 1,000 patients at risk of recurrence and compared the combination with pembrolizumab alone, but detailed phase 3 data had not yet been released at the time of reporting [4].
Why it matters: This is the first mRNA cancer vaccine reported to have reached this stage of development, potentially extending mRNA technology from infectious-disease prevention to individualized cancer treatment [4]. Because surgery may leave patients at risk of recurrence, the approach is designed to help the immune system recognize tumor-specific targets after removal [3][4].
Key insights: Researchers sequence tumor and healthy tissue to identify cancer-driving mutations, then use algorithms to select neoantigens associated with the individual tumor [4]. | An mRNA molecule encodes instructions for those targets, is packaged in a lipid nanoparticle and is injected to train the immune system to attack matching cancer cells [4]. | The phase 3 comparison tested the personalized vaccine plus pembrolizumab against pembrolizumab alone in more than 1,000 patients [4]. | The reported 49% reduction in recurrence or death should not be treated as a fully disclosed phase 3 estimate: one account associated it with five-year follow-up [3], while another said phase 3 details remained unreleased and linked 49% to the earlier phase 2 trial [4].
Cheatsheet facts: What changed: The personalized mRNA regimen met the primary goal of a phase 3 melanoma trial, according to the companies, although detailed data were still pending [4]. | Why now: More than 1,000 post-surgery patients were studied, moving individualized neoantigen therapy to the final clinical-testing stage before a potential FDA request [4]. | Watch next: Watch for presentation of the complete phase 3 efficacy and safety data, followed by any FDA submission and evaluation [4].